$INSM

Lewis William sold $1.3M of INSM

Lewis William (Chair and CEO) sold 10,699 shares of INSMED Inc (INSM) at an average of $117.40 ($116.55–$118.52, $1.26M total) across 3 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jul 10, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (size, price range, and post-transaction holdings) but does not introduce new fundamentals.

02

Market read

This is primarily a sentiment and positioning datapoint for INSM, not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the signal is usually weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-10 after trades dated 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc, reporting open-market sales by the CEO and Chair.

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CEO and Chair Lewis William sold 10,699 shares in open-market trades under a pre-arranged 10b5-1 plan for about $1.26M.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not include new operating, regulatory, or financial guidance.

Market effects

No sector-level implications disclosed; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

A large CEO sale can be interpreted as liquidity management rather than bearish conviction because it is explicitly under a pre-arranged 10b5-1 plan.

Key entities

  • INSMED Inc

    Company whose Form 4 insider sale is disclosed.

  • Lewis William

    Chair and CEO who sold 10,699 shares under a pre-arranged 10b5-1 plan.

Related articles

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.